Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Effect of Oestrogen During Menopause on Risk and Age at Onset of Alzheimer's Disease
Lancet 348:429-432, 4201996., Tang,M.X.,et al, 1996
Estrogen Replacement Therapy and Risk of Alzheimer Disease
Arch Int Med 156:2213-2217, Paganinni-Hill,A.&Henderson,V.W., 1996
Do Nonsteroidal Anti-Inflammatory Drugs Decrease Risk for Alzheimer's Disease, Rotterdam Study
Neurol 45:1441-1445, Andersen,K.,et al, 1995
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993